Key facts
- Sensius’s last known valuation is $44.0M (May 2025).
- It has raised $21.5M; the latest was Later Stage VC ($16.9M) in May 2025.
- Notable investors include European Innovation Council, European Commission, UCEA Capital Partners, Coöperatieve Rabobank., Coöperatieve Rabobank — 14 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Sensius
- ·The full record, as it builds
Funding rounds
No funding rounds for Sensius are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Sensius
Developer of a thermotherapy system designed to improve treatment outcomes for head and neck cancer patients. The company offers a hyperthermia system with integrated microwave sources and interactive software, enabling oncology clinics to enhance traditional therapies and reduce side effects for patients.
- Sector
- Healthcare
- HQ
- Rotterdam, Netherlands
- Founded
- 2015
- Employees
- 30
- Website
- sensiusthermotherapy.com/
- Ownership
- Privately Held (backing)
Sensius doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Sensius shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Sensius in its N-PORT filings yet. We sweep new filings monthly.